HOME > Conference > Plenary Speech & Special Speech
BIO Korea 2008 Conference promises to be another outstanding academic and professional development experience. We invite you to join us in Osong to exchange latest knowledge and technology on the current biotechnology issues, discover challenges, and upgrade yourself for your future. We are proud to offer you 13 Specialized Learning Tracks and 39 Educational Sessions touching all levels of biotechnology and covering numerous topics of biotechnology. Also, the conference includes plenary sessions and special sessions with distinguished speakers. You will leave the conference energized with great ideas you can use and connections that will provide you support throughout the year.
Plenary Speech I
 | Dr. William J. Rutter Chairman & CEO Synergenics, LLC |
|---|
Dr. Rutter is Chairman and CEO of Synergenics, LLC, Chairmen Emeritus of Chiron Corporation and Horzstein Professor of Biochemistry Emeritus at the University of California, San Francisco (UCSF). Dr. Rutter served as chairman of the Department of Biochemistry and Biophysics at the UCSF where he played a key role in developing recombinant DNA technology. He has published 381 scientific articles and holds 26 patents. His lab made several early contributions in biotechnology, including the first cloning of the insulin gene and sequencing of the Hepatitis B virus, and the formation of Hepatitis B pseudoparticles in yeast. This led to the formation of the Hepatitis B vaccine, the first vaccine ever based on recombinant DNA methodology. |
Plenary Speech II
 | Prof. Sir Ian Wilmut Director & Professor Centre for Regenerative Medicine, University of Edinburgh |
|---|
Prof. Sir Ian Wilmut is an English embryologist and is currently the director of MRC Centre for Regenerative Medicine and professor of Reproductive Science, University of Edinburgh. He is best known as the man who played a supervisory role in the team that in 1996 first cloned a mammal, a Finn Dorset lamb named Dolly in 1996. He was granted an Order of the British Empire in 1999 for services to embryo development and has received a knighthood in the Queen’s New Year Honours in 2008. He is currently a member of board International Society for Stem Cell and an editor in chief of Cloning and Stem Cells. |
Plenary Speech III
 | Dr. O Young Lee Advisor JoongAng Ilbo |
|---|
Dr. Lee, O Young is widely known in Korea for his articles, essays and critical writings, covering a vast range of topics such as arts, literature, social, philosophical, cultural, and political issues. In 1960, Dr. Lee began to serve as an editorialist with a number of major daily newspapers and later contributed countless of outstanding columns to their pages. Dr. Lee is a polymath of international stature, perhaps best known abroad for his role in planning the opening and closing ceremonies of the 1988 Seoul Olympic Games. In 1990, he was appointed to be the Republic of Korea's first Minister of Culture, a position he held until 1991. He is now a distinguished honorary professor at Ewha Academy for advanced studies, and advisor of the JoongAng Ilbo. |
Special Speech I Hepatitis C Virus
: Challenge and Advancement of Viral Vaccine Development
 | Track 5. Vaccine / Oct. 8, 2008, 14:00~14:50 |
|---|---|
| Dr. Jang H. Han Director Novartis |
Dr. Jang H. Han is the director of HCV Vaccines Research of Novartis. He was responsible for HCV vaccine research and HDV siRNA inhibitor research as a director, Molecular biology and biochemistry research as research director at Chiron Corporation. He taught Life Science at Pohang University of Science and Technology. He worked for hormone Research Institute at the Univeristy of California, San Francisco, USA. He holds 11 patents and has 66 publications. Also, he stands on the platform as a speaker at the international conference many times. |
Special Speech II Merck's Partnering Strategy in the Asia-Pacific Region
 | Track 8. Business Development / Oct. 9, 2008, 10:00~11:00 |
|---|---|
| Dr. Gregory J. Wiederrecht Vice President & Head, External Scientific Affairs Worldwide Licensing & External Research, Merck & Co., Inc. |
Dr. Greg Wiederrecht is the Vice President and Head of the External Scientific Affairs department of the Merck Research Laboratories division of Merck & Co., Inc. External Scientific Affairs is responsible for the scientific assessment of all licensing and partnering opportunities for Merck. Merck is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and arkets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. He got his Ph.D. in biochemisty from Massachusetts Institute of Technology and joined Merck in 1989. |
